Financial news outlets, stock market analysis

FTC Extends Review of Novo Holdings' $16.5 Billion Catalent Acquisition

May 3, 2024, 03:05 PM

The U.S. Federal Trade Commission (FTC) has issued a second request for more information regarding the $16.5 billion acquisition of Catalent by Novo Nordisk's parent company, Novo Holdings. This move, part of an extended antitrust review, could delay the deal by an additional 30 days. The request reflects the FTC's ongoing scrutiny of the transaction amid concerns from other pharmaceutical groups and contract manufacturers.